Teva Pharmaceutical Industries Ltd.

Regulatory Filings • Feb 20, 2024

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

(Print or Type Responses)

1. Name and Address of Reporting Person Francis Richard D.	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 02/15/2024	Officer (give title below) Other (specify below) President and CEO
(Street) Tel Aviv, L3 6944020 (City) (State) (Zip)	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

l .Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) any	l 2A. Deemed Execution Date, if Code (Month/Day/Year)	3. Transaction (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership of Indirect Form: Direct (D) Ownership	7. Nature Beneficial
			Code		Amount	(A) Or (D)	Price		or Indirect (Instr. 4) (1) (Instr. 4)
Ordinary Shares (1)	02/15/2024		M		161,655	A	(2)	161,655	D
'Ordinary Shares (1)	02/15/2024		ડુ(3)		74.530 (4)	D	S 13.15141	87,125	D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

FORM 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
e.g. . puts. calls, warrants, ontions, convertible securities)

1. Title of Derivative	Conversion Date	3. Transaction	3A. Deemed Execution Date, if Transaction Derivative	4			5. Number of	6. Date Exercisable and Expiration Date		17. Title and Amount of Underlying		Derivative Derivative	8. Price of 9. Number of	10 Ownership of Indirect	11. Nature
Security (Instr. 3)	Price of Derivative Security	or Exercise (Month/Day/Year)	anv (Month/Day/Year) (Instr. 8)	Code		Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		Securities (Instr. 3 and 4)		Security Securities (Instr. 5) Beneficially Owned Following Reported	Transaction(s)	Form of Derivative Ownership Security: Direct (D) or Indirect (D)	Beneficial (Instr. 4)
				Code		(A)	(D)	Date Exercisable Date	Expiration Title		Amount or Number of Shares		(Instr. 4)	(Instr. 4)
Restricted Share Units	(2)	02/15/2024		M			161,655	(6)	(6)	Ordinary Shares (1)	161,655	\$ 0	323,311	D

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 1. Each restricted share unit represent a comments on at the option of the option of the Himan Recources and Compensation Committee, the cast valle of one ordinary share.
• 1. The transaction reported in this Form 4 was effected pursuant to a Rule 1065-1 trading plan adopted by the reporting person on November 13, 2023.
• 1. Represents the number of shares required to be sold by the resertan withouting obligations in comection with the resting of the restricted share units listed in Table II.
• 1. The price reported in Column 4 is a weighted and in multiple transactions at prices ranging from \$1.09 to \$1.24, includive. The reportung preson underskes to provide, upon request by the SEC staff, the issuer, full information regarding the number of shares sold at each separate price.
• 1. Restricted share units were granted on February 15, 2023, with 16,655 vesting on each of February 15, 2025, and 161,656 vesting on Foruxy 15, 2026.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis 02/20/2024

"" Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information this form are not required to respond unless the form displays a currently valid OMB Number.